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Abstract Here we examined T cell responses to two analogs of
a chimeric peptide encoding a known B and a known T cell
epitope. In one of the analogs, the B cell epitope existed in a
random conformation whereas it was restricted within a
disulfide-bonded cyclic loop in the other. Immunization of these
peptides in mice revealed that the latter peptide was significantly
poorer at priming T cells and our preliminary results suggest this
could be the result of differential processing of the two analogs.
While primary T cell responses were sensitive to the influence of
conformation, secondary responses were not discriminatory for
the two antigens confirming the differences in activation
requirements for primary and secondary T cell responses.
Further, our studies also suggest that the priming efficacy of a
T cell epitope is influenced by its structural environment.
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1. Introduction
A viable T-dependent humoral response hinges on the abil-
ity of an antigen to appropriately prime speci¢c B and T
lymphocytes. Subsequent progression is then driven by the
e⁄ciency with which such antigen-activated B cells can recruit
help from the antigen-speci¢c T helper cell pool [1]. Antigen-
activated B and T lymphocytes engage in a cognate interac-
tion, leading to reciprocal proliferation and di¡erentiation
into e¡ector and memory populations [2].
While activated T cells play a pivotal role in driving humor-
al responses, we have recently shown that primed T cells are
also critical in de¢ning the spectrum of B cell ¢ne speci¢cities
that are positively selected from the multitude of clonotypes
that are initially activated [3]. The available pool size of pri-
mary antigen-activated T cells serves as a rate-limiting deter-
minant that enforces a competitive process to select for high
a⁄nity clones [3]. It is the successful subset that dominates the
population of B cells contributing to the later stages of a
primary humoral response [3]. Thus, e¡ective priming of
CD4 T cells by an antigen is critical in elaborating not only
the quantitative aspects of a humoral response, but also the
antibody speci¢cities that constitute it.
The present report continues our earlier investigations on
modulation of B cell responses using analogs of a chimeric
peptide encoding a known B and a known T cell epitope [3^7].
We show here that the e⁄cacy of T cell priming in such
constructs can be signi¢cantly a¡ected by the imposition of
a conformational constraint on the £anking B cell epitope.
Interestingly however, although T cell priming was signi¢-
cantly diminished, secondary T cell responses were relatively
unaltered. In addition to con¢rming di¡erences in require-
ments for primary and secondary T cell activation, our results
also suggest that the e⁄ciency or priming by individual T cell
epitopes on a multi-determinant antigen may be sensitive to
the structural milieu in which they occur.
2. Materials and methods
2.1. Materials
Horseradish peroxidase-labeled anti-mouse IgG (heavy chain-spe-
ci¢c) was purchased from Sigma Chemical Co. (St. Louis, MO,
USA). F-moc amino acid derivatives were purchased from Novabio-
chem (Laufel¢ngen, Switzerland).
2.2. Peptide synthesis
Peptides were synthesized on a Milligen 9050 automated peptide
synthesizer using F-moc chemistry [8]. Crude peptide was puri¢ed to
at least 95% purity by reverse phase HPLC. For the synthesis of
peptide CysCT3, the side chain protecting group used for cysteine
was the acetamidomethyl (Acm) group. Subsequent to synthesis and
cleavage from solid support, simultaneous deprotection of the cysteine
side chains and oxidation to form intramolecular disul¢de bonds was
achieved with iodine in acetic acid [9].
The correct identity of all peptides synthesized was ascertained both
by amino acid analysis and by mass spectrometry.
2.3. Animals and immunizations
Female BALB/c mice (6^8 weeks old) were obtained from the small
animal facility at the National Institute of Nutrition (Hyderabad,
India). Immunizations with either peptide PS1CT3 or CysCT3 were
i.p. at a dose of 50 Wg/mouse as an emulsion in Freund’s complete
adjuvant (CFA). In experiments with CT3 prepriming, peptide CT3 at
a dose of 50 Wg/mouse (CFA, base of tail) was administered 7 days
prior to immunization with peptide CysCT3.
ELISA and LNC proliferation assays were essentially as described
earlier [6].
3. Results
3.1. Immunogenicity of peptides PS1CT3 and CysCT3
Peptide PS1CT3 is a chimeric peptide with the sequence
HQLDPAFGANSTNPDGGDIEKKIAKMEKASSVFNVV-
NS. The ¢rst 15 residues of this sequence (segment PS1) rep-
resent a well characterized B cell epitope derived from the
envelope protein of hepatitis B virus [10]. Residues 18^38 (seg-
ment CT3) correspond to a promiscuous T cell epitope
present on the circumsporozoite protein of the malaria para-
site Plasmodium falciparum [11]. Separating the B and T cell
epitopes is a spacer of two glycine residues at positions 16 and
17. Prior analysis of peptide PS1CT3 by circular dichroism
spectroscopy had revealed that this peptide exists in a random
distribution of conformations in aqueous solutions [3]. Immu-
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nization of BALB/c mice with peptide PS1CT3 has been
shown to result in a T-dependent primary and secondary
IgG response that is exclusively directed against a tetrapeptide
epitope between positions 4 and 7 (sequence: DPAF) [3]. In
the present study we also employed an analog of peptide
PS1CT3 where positions 1 and 10 were substituted with cys-
teine residues. Subsequent air oxidation resulted in the gen-
eration of an intramolecular disul¢de bond, to yield a peptide
where the ¢rst 10 residues were locked within a cyclic loop
(peptide CysCT3).
To compare the immunogenicity of the above two peptides,
groups of BALB/c mice were immunized with a single dose of
either peptide PS1CT3 or peptide CysCT3 and speci¢c serum
antibody levels were monitored as a function of time. As
shown in Fig. 1 the anti-CysCT3 titers were signi¢cantly lower
than those obtained against peptide PS1CT3. This was true
over the entire range of time points evaluated. It would thus
appear that peptide CysCT3 is markedly less immunogenic
than peptide PS1CT3.
3.2. Peptide CysCT3 primes T cells poorly
To examine whether the di¡erences in immunogenicity
could have resulted from di¡erences at the level of T cell
priming, proliferative responses of lymph node cells (LNCs)
from mice immunized with either peptide were measured.
While LNCs from peptide PS1CT3-immunized mice yielded
signi¢cant proliferative responses, those from CysCT3-primed
mice were markedly diminished (Fig. 2). This was true regard-
less of whether the challenge antigen employed was the ho-
mologous peptide (Fig. 2A) or a peptide representing the CT3
segment of these immunogen molecules (Fig. 2B). Further-
more, challenge of CysCT3-primed LNCs with peptide
PS1CT3 resulted in stimulation index values identical to those
obtained with peptide CysCT3 as the challenge antigen (data
not shown).
The poor T cell priming ability of peptide CysCT3 could be
either due to altered secondary structure of the neighboring B
cell epitope segment, or a consequence of the nature of the
substitutions performed. To discriminate between these two
possibilities we synthesized a linearized analog of peptide
CysCT3 where the cysteine-sulfhydryl groups were blocked
as acetamidomethyl derivatives (peptide Cys(Acm)CT3). Im-
munization of BALB/c mice with peptide Cys(Acm)CT3 fol-
lowed by an examination of LNC proliferative responses re-
vealed that this analog was far more potent at priming T cells
than peptide CysCT3 (Fig. 3). Thus, it would appear that the
attenuated ability of peptide CysCT3 to prime speci¢c T cells
is a consequence of the altered conformation of the £anking B
cell epitope.
3.3. Poor B cell immunogenicity of peptide results from
ine⁄cient T cell priming
It was of interest to ascertain whether the poor antibody
response to peptide CysCT3 in Fig. 1 was due to insu⁄cient T
cell priming. For this, mice were ¢rst preprimed with peptide
CT3 7 days prior to immunization with peptide CysCT3. Pre-
priming with peptide CT3 has been shown to function by
increasing the frequency of antigen-activated T cells available
at the time of antigen exposure to naive B cells [5]. An anal-
ysis of anti-CysCT3 IgG levels in sera collected subsequently
revealed that CT3 prepriming resulted in a marked improve-
ment in anti-CysCT3 titers over those from mock-preprimed
mice. This clearly suggests that the poor B cell immunogenic-
ity of peptide CysCT3 was likely to be due to the presence of
a limiting amount of T cell help. This possibility could be
further validated by comparing primary anti-peptide IgG
titers obtained in mice immunized with either peptide CysCT3
or Cys(Acm)CT3. In these experiments we observed that pep-
tide Cys(Acm)CT3 was at least ¢ve-fold more immunogenic,
in terms of IgG antibody levels, than peptide CysCT3 (data
not shown).
3.4. Peptides PS1CT3 and CysCT3 are equally competent at
eliciting secondary T cell responses
Although the analogs studied here di¡ered markedly in
their abilities to prime for a T cell response, we also compared
their potencies at recalling a preprimed population of antigen-
speci¢c T cells. For this, LNCs from mice primed with either
peptide CT3 or PS1CT3 were challenged in vitro with varying
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Fig. 1. Relative immunogenicity of peptides PS1CT3 and CysCT3.
Groups of ¢ve mice each were immunized either with peptide
PS1CT3 (a) or with peptide CysCT3 (b) as described in Section 2.
Blood was collected at indicated time points and sera within a
group pooled. Peptide-speci¢c IgG antibody levels were quantitated
by ELISA. The ¢gure shows a representative of ¢ve independent ex-
periments.
Fig. 2. Primary T cell responses induced by peptide PS1CT3 and its
analogs. LNCs from mice primed with either peptide PS1CT3 (a),
peptide CysCT3 (b) or peptide Cys(Acm)CT3 (O) were cultured in
vitro with the indicated concentrations of either the homologous
peptide (A) or peptide CT3 (panel B). Lymphocyte proliferation
was measured as counts of [3H]thymidine incorporated. Mean back-
ground counts varied between 1500 and 2000 cpm. Values are pre-
sented as the stimulation index (mean þ S.E.M. of quadruplicate
sets), which represents the ratio of counts obtained at a given con-
centration of antigen over that obtained in the absence of any chal-
lenge antigen. The ¢gure shows a representative of ¢ve independent
experiments.
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concentrations of either peptide PS1CT3 or peptide CysCT3
and the resulting proliferation was measured. As shown in
Fig. 4, recall proliferative responses elicited by peptide
CysCT3 were comparable to those by peptide PS1CT3 both
in PS1CT3- (panel A) and CT3- (panel B) primed LNCs.
Thus, although peptides PS1CT3 and CysCT3 di¡er in their
abilities to prime T cells they are equally pro¢cient at recalling
a preprimed antigen-speci¢c T cell population.
Pretreatment of CT3-primed LNCs with chloroquine abol-
ished recall responses to both peptides PS1CT3 and CysCT3
(stimulation index values 6 2.0), con¢rming our earlier obser-
vations [6] that PS1CT3 and its analog peptides require proc-
essing prior to appropriate presentation in association with
MHC class II molecules.
4. Discussion
A productive immune response requires optimal activation
of both antigen-speci¢c B and T lymphocytes. Recognition ^ a
prerequisite for activation ^ by B lymphocytes involves a di-
rect encounter between the B cell antigen receptor (BCR) and
target antigen, the latter in its native form [12]. Consequently,
both qualitative and quantitative aspects of a humoral re-
sponse can be expected to be in£uenced by the structural
context in which a given antigenic determinant is present. In
contrast, T cell recognition is restricted to peptides in an ex-
tended conformation ^ generated by processing of the parent
antigen within antigen-presenting cells (APCs), and presented
in association with MHC class II molecules [13,14]. As a
result, recognition of an antigenic determinant by T cells is
expected to be independent of the structural milieu of its
origin. Although true in principle, activation of an antigen-
speci¢c T cell is nevertheless variably a¡ected by factors that
in£uence the e⁄cacy with which an APC can present the
appropriate ligand to it. Thus, for example, extent of antigen
uptake by APCs, rate and speci¢city of antigen processing,
and a⁄nity of the resulting peptides for the MHC class II
molecule have all been shown to serve as regulatory in£uences
on T cell activation [15^17].
The present study describes a surprising e¡ect of conforma-
tion of a £anking domain on in vivo priming by a T cell
epitope. Peptide CysCT3, where the neighboring B cell epi-
tope sequence was held in a disul¢de-bonded loop, was dis-
tinctly less immunogenic than its parent peptide PS1CT3
where the PS1 segment existed in a random distribution of
conformations. The poor anti-CysCT3 IgG antibody response
was shown to result from its inability to prime T cells as
e¡ectively as peptide PS1CT3. Furthermore, it could also be
demonstrated that the attenuated T cell priming e⁄cacy of
peptide CysCT3 was purely a consequence of the altered
structure of the PS1 segment rather than due to the nature
of the substitutions performed. Interestingly however, while
primary T cell responses were sensitive to the structural envi-
ronment of the CT3 segment, both peptides PS1CT3 and
CysCT3 proved equally competent at recalling secondary T
cell responses in vitro. This latter result con¢rms a di¡erence
in requirements for activation of primary and secondary T cell
responses [18].
The mechanism by which an altered conformation of the
PS1 segment inhibits T cell priming by peptide CysCT3 is
currently unclear. However, it is likely that the di¡erence is
experienced at the level of antigen presentation, presumably
by dendritic cells and/or macrophages ^ the principal cell
types implicated in priming of CD4 T cells [19]. Such var-
iance could arise as a consequence of either altered antigen
uptake or alterations at the level of antigen processing.
Although our observations that both peptides PS1CT3 and
CysCT3 elicit nearly identical recall responses may appear
to rule out dramatic di¡erences in processing of the two pep-
tides, we cannot ignore the possibility of minor di¡erences
that exert their in£uence at the level of primary but not sec-
ondary T cell responses. Furthermore, the ¢nding of compa-
rable recall e⁄ciencies of peptides PS1CT3 and CysCT3, re-
gardless of whether the LNCs were primed with peptide
CysCT3, PS1CT3 or CT3, strongly points towards quantita-
tive rather than qualitative di¡erences in antigen presentation
from the two peptides.
Our demonstration here that the structural environment in
the vicinity of a T cell epitope can a¡ect its ability to prime T
cells raises some interesting implications. This is particularly
true with respect to the more complex multi-determinant anti-
gens such as proteins. It is generally believed that immune
responses are initiated by presentation of epitopes for CD4
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Fig. 3. Enhanced immunogenicity of peptide CysCT3 in CT3-pre-
primed mice. Groups of four mice each were either preprimed with
peptide CT3 (group 2) or mock-primed with adjuvant alone (group
1). Seven days later, both groups were immunized with peptide
CysCT3. Sera were collected at weekly intervals and anti-CysCT3
IgG titers measured by ELISA. Data shown here are for sera ob-
tained from individual mice at 14 days after CT3 immunization.
Fig. 4. T cell recall responses to peptides PS1CT3 and CysCT3.
LNCs from mice primed with either peptide PS1CT3 (A) or peptide
CT3 (B) were challenged with indicated concentrations of either
peptide PS1CT3 (a) or peptide CysCT3 (b) and proliferation meas-
ured as described for Fig. 2. Data presentation is as described for
Fig. 2. The ¢gure is a representative of three separate experiments.
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T cells by antigen non-speci¢c APCs [20]. The poor e⁄ciency
of non-speci¢c uptake mechanisms, leading to low concentra-
tions of peptide fragments generated intracellularly, has been
proposed to account for the selective immunodominance of
peptide epitopes in primary CD4 cell responses [20]. The
results presented here suggest that local environmental in£u-
ences, by modifying T cell priming e⁄cacies of individual T
cell epitopes, can add yet another variable in de¢ning the
repertoire of T cell speci¢cities generated in a primary re-
sponse to protein antigens. Indeed, in this connection, a recent
study has identi¢ed the existence of a predictive correlation
between immunodominant T cell epitopes, and nearby struc-
turally unstable segments in protein antigens [21].
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